Schedule 13D ownership disclosure

Janux Therapeutics Inc

Security class unavailable · CUSIP: 47103J105

Event date: 2024-09-12

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,959,175
Percent of class
5.7000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-24-100347
Form type
SC 13D/A
Filer
Avalon Ventures XI, L.P.
CIK
CIK 1652901
Filed
Sep 16, 2024
Reporting period
Sep 12, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub